Related Experiment Video
Updated: Feb 16, 2026
08:03
In Vivo Mouse Model of Spinal Implant Infection
Published on: June 23, 2020
2.8K
Baicalin alleviates osteomyelitis by regulating TLR2 in the murine model
Tianyi Wu1, Zhenjun Weng1, Jia Xu1
1Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai 200033, China.
Pathogens and Disease
|December 19, 2017
Summary
Baicalin, a compound from Scutellaria lateriflora, effectively treats osteomyelitis by reducing bone destruction and inflammation. Its therapeutic effects are linked to the regulation of Toll-like receptor 2 (TLR2) signaling.
Area of Science:
- Pharmacology
- Immunology
- Orthopedics
Background:
- Osteomyelitis is bone inflammation caused by pathogens.
- Toll-like receptor 2 (TLR2), inflammatory cytokines, and MAPK signaling pathways are implicated in osteomyelitis pathogenesis.
- Baicalin, derived from Scutellaria lateriflora, exhibits anti-inflammatory properties.
Purpose of the Study:
- To investigate the potential of baicalin in treating osteomyelitis.
- To elucidate the role of TLR2 in baicalin's anti-osteomyelitis effects.
Main Methods:
- Mice and MC3T3-E1 cells were infected with Staphylococcus aureus and treated with baicalin.
- Bone destruction, TLR2 expression, osteogenic markers, serum inflammatory factors, and MAPK pathway activation were analyzed.
- TLR2 was knocked down using shRNA to assess its role in baicalin's efficacy.
Main Results:
- Baicalin treatment alleviated bone destruction in osteomyelitis models.
- Baicalin reduced the expression of TLR2, alkaline phosphatase, osteopontin, and collagen type I.
- Serum levels of IL-1β, IL-6, and CRP were decreased by baicalin, as was MAPK pathway activation.
- Baicalin's inhibitory effect on osteomyelitis was dependent on TLR2 inhibition.
Conclusions:
- Baicalin demonstrates therapeutic potential against osteomyelitis.
- Baicalin alleviates osteomyelitis by modulating TLR2 signaling and downstream inflammatory pathways.
